+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Apalutamide"

Prostate Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Prostate Cancer Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
From
From
From
From
From
Apalutamide - Launch Insight, 2019 - Product Thumbnail Image

Apalutamide - Launch Insight, 2019

  • Report
  • January 2019
  • 50 Pages
  • Global
From
Drug Overview: apalutamide - Product Thumbnail Image

Drug Overview: apalutamide

  • Drug Pipelines
  • January 2018
  • 18 Pages
  • Global
From
Drug Overview: darolutamide - Product Thumbnail Image

Drug Overview: darolutamide

  • Drug Pipelines
  • January 2018
  • 17 Pages
  • Global
From
From
  • 15 Results (Page 1 of 1)
Loading Indicator

Apalutamide is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of androgens, hormones that can cause prostate cancer cells to grow. Apalutamide is used in combination with other treatments, such as hormone therapy, to slow the growth of prostate cancer. It is approved by the US Food and Drug Administration (FDA) for the treatment of non-metastatic castration-resistant prostate cancer. Apalutamide is a relatively new drug, and is part of a growing class of prostate cancer treatments. It is one of several drugs that have been developed to target androgen receptors, which are proteins that can cause prostate cancer cells to grow. Other drugs in this class include enzalutamide and abiraterone. Apalutamide is available in the US and Europe, and is marketed by several pharmaceutical companies. These include Janssen Pharmaceuticals, Astellas Pharma, and Bayer. Show Less Read more